Today: 21 May 2026
Browse Category

NYSE:IOT 5 December 2025 - 6 March 2026

Samsara Stock Jumps After Earnings Beat, 2027 Outlook Tops Views

Samsara Stock Jumps After Earnings Beat, 2027 Outlook Tops Views

Samsara reported fourth-quarter revenue of $444.3 million, up 28%, and adjusted earnings of 18 cents per share, both above analyst estimates. The company forecast first-quarter revenue of $454 million to $456 million and fiscal 2027 revenue near $2 billion. Annual recurring revenue rose 30% to $1.89 billion. Samsara ended fiscal 2026 with 3,194 customers generating over $100,000 in ARR.
6 March 2026
··
Samsara (IOT) Shows Sticky Growth and Operating Leverage as Strategy (MSTR) Buys 10,645 More Bitcoin: Key Updates for Dec. 15, 2025

Samsara (IOT) Shows Sticky Growth and Operating Leverage as Strategy (MSTR) Buys 10,645 More Bitcoin: Key Updates for Dec. 15, 2025

Strategy (NASDAQ: MSTR) disclosed it bought 10,645 bitcoin for $980.3 million between Dec. 8–14, funded by selling 4.8 million shares for $888.2 million. The company now holds 671,268 bitcoin, worth $50.33 billion at purchase price. Strategy kept its spot in the Nasdaq 100 after the annual review, though index eligibility questions remain.
15 December 2025
····
Samsara (IOT) Stock Today: Q3 FY2026 Earnings Beat, First GAAP Profit and a Wave of New $50 Price Targets

Samsara (IOT) Stock Today: Q3 FY2026 Earnings Beat, First GAAP Profit and a Wave of New $50 Price Targets

Samsara Inc. (NYSE: IOT) reported its first-ever GAAP profit and 29% revenue growth for Q3 FY2026, with revenue reaching $416 million. Shares traded around $40.71 on December 5, up 4% for the day but still 6–7% below year-to-date levels and well under the February peak. Wall Street price targets hover near $50. Market cap stands near $23.5 billion.
5 December 2025
···

Stock Market Today

  • 3 Middle Eastern Penny Stocks With Market Caps Over US$3M
    May 21, 2026, 12:54 AM EDT. Investors cautious amid geopolitical risks and volatile oil. Three Middle Eastern penny stocks spotlighted for strong financials despite challenges. Airtouch Solar Ltd (market cap ₪15.08M) cut losses 11% annually, with revenue of ₪38.03M but increased net loss of ₪8.12M, maintaining more cash than debt and a 3-year cash runway. Big Tech 50 R&D (market cap ₪10.75M) is pre-revenue, reducing net loss to $2.85M, debt-free with 3+ years cash runway, led by an experienced board. Sonovia Ltd (market cap ₪9.27M) develops anti-bacterial textiles, details limited in the report. These firms show potential in under-the-radar Middle Eastern markets amid uncertain environment.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop